ARS Pharmaceuticals Inc
SPRY
Market Cap$1.38B
Close$
$-1.14
106.9% downside
Current Fair Value
106.9% downsideOvervalued by 106.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.38 Billion |
|---|---|
| Enterprise Value | $1.34 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.57 |
| Beta | 0.77 |
| Outstanding Shares | 96,827,687 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -30.65 |
|---|---|
| PEG | -13.34 |
| Price to Sales | - |
| Price to Book Ratio | 8.26 |
| Enterprise Value to Revenue | 13.97 |
| Enterprise Value to EBIT | -49.4 |
| Enterprise Value to Net Income | -86 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About ARS Pharmaceuticals Inc
54 employeesSilverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administe...